Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Evaluation of Omega-3 Fatty Acid

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03017651
Recruitment Status : Completed
First Posted : January 11, 2017
Last Update Posted : May 16, 2017
Sponsor:
Collaborator:
Miami Research Associates
Information provided by (Responsible Party):
Nestlé

Brief Summary:
This protocol will determine the pK profile of two different omega-3 fatty acid supplements on plasma EPA and DHA levels.

Condition or disease Intervention/treatment Phase
Overweight and Obesity Dietary Supplement: OM3-supplement 1 Dietary Supplement: OM3-supplement 2 Phase 1

Detailed Description:
This protocol is to assess the omega-3 blood levels of DHA and EPA following a single dose administration of study products by means of pharmacokinetics over a 24 hour period of time (post-dose).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Other
Official Title: An Evaluation of a Proprietary Omega-3 Fatty Acid Incorporated Into a MAG on Blood EPA and DHA Levels: a PK Study
Study Start Date : November 2016
Actual Primary Completion Date : December 2016
Actual Study Completion Date : May 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: OM3-supplement 1
1 g capsule for OM3-supplement 1 given once
Dietary Supplement: OM3-supplement 1
1g of OM3-supplement 1 will be given to subjects to look at DHA/EPA blood absorption

Active Comparator: OM3-supplement 2
1 g capsule for OM3-supplement 2 given once
Dietary Supplement: OM3-supplement 2
1g of OM3-supplement 2 will be given to subjects to look at DHA/EPA blood absorption




Primary Outcome Measures :
  1. AUC0-t [ Time Frame: from 0 to 24 hours ]
    The plasma pharmacokinetics (AUC0-t) resulting from a single oral dose administration will be estimated from 0 to 24 hours post-dose


Secondary Outcome Measures :
  1. AUC0-inf [ Time Frame: from 0 to infinity ]
    The plasma pharmacokinetics (AUC0-t) resulting from a single oral dose administration will be estimated from o to infinity

  2. Cmax [ Time Frame: between 0 and 24 hours ]
    The plasma pharmacokinetics (Cmax) resulting from a single oral dose administration will be estimated from 0 to 24 hours post-dose

  3. tmax [ Time Frame: between 0 and 24 hours ]
    The plasma pharmacokinetics (tmax) resulting from a single oral dose administration will be estimated from 0 to 24 hours post-dose

  4. t½ [ Time Frame: between 0 and 24 hours ]
    The plasma pharmacokinetics (t1/2) resulting from a single oral dose administration will be estimated from 0 to 24 hours post-dose



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  1. Male or female subjects between 18 and 65 years old (inclusive)
  2. Body Mass Index (BMI) between 25.0 and 34.9 kg/m2 (inclusive) at Screening.
  3. Subjects with normal or moderately elevated lipidemia (borderline lipids as defined by the AACE - Total cholesterol ≤ 240 mg/dl; LDL ≤ 160 mg/dl; TG ≤ 199 mg/dl).
  4. Subjects with no clinically significant findings in the physical examination, medical history, vital signs, clinical laboratory test (hematology and serum chemistry) results and as deemed by the Investigator.
  5. Subjects must understand and agree to comply with the requirements of the study and they must be willing to sign the informed consent indicating voluntary consent to participate in the study prior to the initiation of Screening or study related activities.
  6. Male and female subjects of childbearing potential must agree to use one of the following medically acceptable contraceptive methods for the duration of the study: same-sex partner; double barrier (condom, diaphragm or cervical cap with spermicidal foam, gel or cream); IUD (with or without hormones) in place or hormonal contraception (oral, injectable, implantable, transdermal or vaginal) used consecutively for at least 3 months prior to study product administration; vasectomized partner or sterilization by bilateral insertion of Essure® or similar product for 6 months minimum prior to study product administration; bilateral tubal ligation, hysterectomy and/or bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year prior to study product administration

Exclusion Criteria:

  1. Currently using fish oil capsules (supplements or prescription products).
  2. Regular use of omega-3 supplements (defined as greater than 500 mg/week) within 4 weeks of study product administration.
  3. Currently using any medications that may impact dietary fat absorption (i.e., Orlistat, Alli, etc.).
  4. Currently using any medications that may interfere with omega-3 uptake (i.e. blood thinning medication or anticoagulants).
  5. Currently using any lipid lowering medications (i.e. any cholesterol or triglyceride lowering agent).
  6. Currently consuming high amounts of EPA & DHA in the diet (as defined by greater than 200 mg/day by FFQ)
  7. Currently following a self-reported no-fat or ultra-restrictive (less than 15%) Low-Fat Diet
  8. Having the following medical conditions:

    i. Malabsorptive disorders including but not limited to pancreatitis, Crohn's disease, etc.

    ii. Hypertriglyceridemia (as defined by the Inclusion and per PI discretion; Total cholesterol > 240 mg/dl; LDL > 160 mg/dl; TG > 199 mg/dl) iii. Type2 Diabetes Mellitus

  9. Currently a smoker or nicotine user or has been nicotine free for less than 6 months
  10. Use of any systemic medications, including OTC medications, herbal products, dietary supplements or vitamins (not previously listed) within 1 week of study product administration (occasional use of OTC analgesics such as acetaminophen may be allowed as judged by the Investigator)
  11. Evidence or history of allergic or adverse responses to either study product, any of the product excipients or any comparable or similar products
  12. Subjects who are not willing and not able to comply with scheduled visits and the requirements of the study protocol.
  13. Female subjects who are breastfeeding, pregnant or plan to become pregnant during this study.
  14. Current employee or immediate family member of the study sponsor or study site personnel.
  15. Currently participating or have participated in another clinical trial within 4 weeks of study product administration
  16. Donated blood, blood components, or significant loss of blood within 30 days of study product administration
  17. History of a clinically-significant illness within 4 weeks of study product administration
  18. History of hospitalization or treatment for clinically-significant drug or alcohol use/abuse within 1 year of dosing.
  19. Subject has poor venous access or difficulty swallowing capsules
  20. Any other issue which, in the judgment of the Investigator, will make the subject ineligible for study participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03017651


Locations
Layout table for location information
United States, Florida
QPS/Miami Research Associates
Miami, Florida, United States, 33143
Sponsors and Collaborators
Nestlé
Miami Research Associates
Investigators
Layout table for investigator information
Principal Investigator: Diane Krieger, MD QPS-MRA
Layout table for additonal information
Responsible Party: Nestlé
ClinicalTrials.gov Identifier: NCT03017651    
Other Study ID Numbers: 16.20.CLI
First Posted: January 11, 2017    Key Record Dates
Last Update Posted: May 16, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Overweight
Body Weight